Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis Meeting Abstract

  

Authors:	Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; Gerdes, H.; Shah, P. M.; Ku, G. Y.; Ilson, D. H.; Capanu, M.; Hechtman, J. F.; Merghoub, T.; Solit, D. B.; Schultz, N.; Janjigian, Y. Y.
Abstract Title:	Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
Meeting Title:	56th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	38
Issue:	15 Suppl.
Meeting Dates:	2020 May 29-31
Meeting Location:	Virtual Conference
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2020-05-20
Language:	English
ACCESSION:	WOS:000560368302174
PROVIDER:	wos
DOI:	10.1200/JCO.2020.38.15_suppl.4559
Notes:	Meeting Abstract: 4559 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/172930